Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
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
wCERyRuedxCYffX0
